Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Meeting slated for Oct. 18-19 has been canceled. No agenda has been set for the next scheduled meeting dates of Dec. 2-3. Most recently, NDAC met jointly with the Arthritis Advisory Committee July 20 to consider the Rx-to-OTC switch of Merck's Flexeril 5 mg (1"The Tan Sheet" July 26, pp. 3-9)

You may also be interested in...

Flexeril Indications Self-Diagnosis Seen As Significant Hurdle By Committee

The ability of patients to accurately detect when they would need to use Flexeril 5 mg (cyclobenzaprine) is a significant hurdle the drug would need to overcome in a switch from the Rx to the OTC environment, according to discussions by FDA's Nonprescription Drugs and Arthritis Advisory Committees July 20.

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts